MI, E., N, L., SA, F., VK, R., ED, P., C, A., . . . K, M. (2024). Impacts of glucagon-like peptide-1 receptor agonists on the risk of adverse liver outcomes in patients with metabolic dysfunction-associated steatotic liver disease cirrhosis and type 2 diabetes. Alimentary pharmacology & therapeutics, 59(9), 1096. https://doi.org/10.1111/apt.17925
Chicago Style (17th ed.) CitationMI, Elsaid, Li N, Firkins SA, Rustgi VK, Paskett ED, Acharya C, Reddy KR, Chiang CW, and Mumtaz K. "Impacts of Glucagon-like Peptide-1 Receptor Agonists on the Risk of Adverse Liver Outcomes in Patients with Metabolic Dysfunction-associated Steatotic Liver Disease Cirrhosis and Type 2 Diabetes." Alimentary Pharmacology & Therapeutics 59, no. 9 (2024): 1096. https://doi.org/10.1111/apt.17925.
MLA (9th ed.) CitationMI, Elsaid, et al. "Impacts of Glucagon-like Peptide-1 Receptor Agonists on the Risk of Adverse Liver Outcomes in Patients with Metabolic Dysfunction-associated Steatotic Liver Disease Cirrhosis and Type 2 Diabetes." Alimentary Pharmacology & Therapeutics, vol. 59, no. 9, 2024, p. 1096, https://doi.org/10.1111/apt.17925.
